Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

Market Cap	36.32B
Revenue (ttm)	1.37B
Net Income (ttm)	870.39M
Shares Out	616.79M
EPS (ttm)	1.39
PE Ratio	42.31
Forward PE	118.55
Dividend	0.12 (0.21%)
Ex-Dividend Date	Nov 7, 2025

Volume	4,737,282
Average Volume	4,208,833
Open	57.41
Previous Close	57.41
Day's Range	57.41 - 59.58
52-Week Range	20.56 - 83.00
Beta	0.95
RSI	43.91
Earnings Date	Mar 31, 2026

About SHA:688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. The company...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 995
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688336

Financial Performance

In 2024, SHA:688336's revenue was 1.19 billion, an increase of 17.70% compared to the previous year's 1.01 billion. Earnings were 704.58 million, an increase of 139.15%.